Pivekimab - CAS 2234335-84-1

Pivekimab is a high-affinity humanised monoclonal antibody targeting CD123 (IL-3RA), which can be used to synthesise the ADC molecule pivekimab sunirine, for the study of acute myeloid leukaemia and blast plasmacytoid dendritic cell neoplasm (BPDCN) .

Immunology/Inflammation related, ADC Antibody, Interleukin

Immunology/Inflammation, Antibody-drug Conjugate/ADC Related

2234250

0.99

-20°C

Ice Packs

Inhibitory Antibodies